Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

898 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.
Stessman HA, Baughn LB, Sarver A, Xia T, Deshpande R, Mansoor A, Walsh SA, Sunderland JJ, Dolloff NG, Linden MA, Zhan F, Janz S, Myers CL, Van Ness BG. Stessman HA, et al. Among authors: zhan f. Mol Cancer Ther. 2013 Jun;12(6):1140-50. doi: 10.1158/1535-7163.MCT-12-1151. Epub 2013 Mar 27. Mol Cancer Ther. 2013. PMID: 23536725 Free PMC article.
Gene expression profiling and multiple myeloma.
Shaughnessy J Jr, Zhan F, Barlogie B, Stewart AK. Shaughnessy J Jr, et al. Among authors: zhan f. Best Pract Res Clin Haematol. 2005;18(4):537-52. doi: 10.1016/j.beha.2005.02.003. Best Pract Res Clin Haematol. 2005. PMID: 16026736 Review.
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.
van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK, Garg TK, Shi J, Moreno-Bost AM, Yun R, Balasa B, Ganguly B, Chao D, Rice AG, Zhan F, Shaughnessy JD Jr, Barlogie B, Yaccoby S, Afar DE. van Rhee F, et al. Among authors: zhan f. Mol Cancer Ther. 2009 Sep;8(9):2616-24. doi: 10.1158/1535-7163.MCT-09-0483. Epub 2009 Sep 1. Mol Cancer Ther. 2009. PMID: 19723891 Free PMC article. Clinical Trial.
NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma.
Yang Y, Zhou W, Xia J, Gu Z, Wendlandt E, Zhan X, Janz S, Tricot G, Zhan F. Yang Y, et al. Among authors: zhan x, zhan f. Oncotarget. 2014 Dec 15;5(23):11986-97. doi: 10.18632/oncotarget.2388. Oncotarget. 2014. PMID: 25230277 Free PMC article.
898 results